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Objective: The inﬂammatory process is a very important stage in the development and
prognosis of acute ischemic stroke (AIS). The monocyte to high-density lipoprotein (HDL)
ratio (MHR) is accepted as a novel marker for demonstrating inﬂammation. However, the
role of MHR as a predictor of mortality in patients with AIS remains unclear.
Methods: We retrospectively enrolled 466 patients who were referred to our clinic within the
ﬁrst 24 hours of symptom presentation and who were diagnosed with AIS between January
2008 and June 2016. Four hundred and eight controls of similar age and gender were also
included. The patient group was classiﬁed into two groups according to 30-day mortality.
The groups were compared in terms of monocyte counts, HDL, and MHR values.
Results: The patient group had signiﬁcantly higher monocyte counts and lower HDL levels;
therefore, this group had higher values of MHR compared to controls. Additionally, the
monocyte count and MHR value were higher, and the HDL level was lower in non-surviving
patients ( p < 0.001). The MHR value was also observed as a signiﬁcant independent variable
of 30-day mortality in patients with AIS ( p < 0.001). The optimum cut-off value of MHR in
predicting the 30-day mortality for patients with AIS was 17.52 (95% CI 0.95–0.98).
Conclusion: Our study demonstrated that a high MHR value is an independent predictor of
30-day mortality in patients with AIS.
© 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Acute ischemic stroke (AIS) is deﬁned as an infarct due to
arterial occlusion [1]. It is the most common emergent
neurological condition, with a high incidence of mortality
and morbidity, especially in the elderly population [1,2].
Among the etiologic factors, large artery atherosclerosis and
cardioembolic causes have a great importance. Atrial ﬁbrilla-
tion (AF) is the most frequent reason for cardioembolic stroke
[2]. Independent of the stroke etiology, there is a growing body
of evidence indicating that the inﬂammatory process is very
critical in the development and prognosis of AIS [3].
Macrophages and monocytes are types of cells that play key
roles in the release of proinﬂammatory cytokines and
contribute to all stages of inﬂammation [4,5]. In particular,
activated monocytes modulate inﬂammatory cytokines dur-
ing the development of chronic inﬂammation and cardiovas-
cular diseases [6,7]. It is known that high-density lipoprotein
(HDL) inhibits the oxidation of low-density lipoprotein (LDL)
and protects the endothelium against the destructive effects of
LDL [8]. In this way, it is thought that HDL has anti-
inﬂammatory effects [8,9]. Recent reports have demonstrated
that the increased monocyte count to HDL ratio (MHR), which
is obtained by dividing the monocyte count by the HDL value,
may be a novel predictor of prognosis in cardiovascular
diseases [10–12]. To our knowledge, however, no study has
evaluated the role of MHR in the process or prognosis of
ischemic stroke in the literature.
In this study, our aim was to retrospectively compare the
MHR values between patients with AIS and controls and to
determine the role of MHR in the 30-day mortality of patients
with AIS.
2. Materials and methods
2.1. Study group
Our study is a single-center retrospective study that included
466 patients who were referred to our clinic within the ﬁrst
24 h of symptoms and diagnosed with AIS between January
2008 and June 2016. The medical history, cranial magnetic
resonance (MR), or computed tomography (CT) imaging
ﬁndings showed the newly occurred ischemic lesion, and
the neurological examination ﬁndings of patients were used in
order to determine the deﬁnitive diagnosis of AIS. There were
no restrictions regarding sex and age among the patients.
Exclusion criteria were systematic acute/chronic inﬂammato-
ry/autoimmune or infectious diseases, chronic connective
tissue diseases, hematological disorders, cancer, severe liver,
kidney or heart failure, acute coronary syndrome within the
past three months, prior acute myocardial infarction, a history
of major surgery or trauma, and chronic alcohol abuse. The
patient group was divided into two subgroups according to the
30-day patient mortality. The patients in the ﬁrst group were
survivors past 30 days, and patients in the second group were
patients who died within 30 days after AIS.
The control group consisted of 408 patients who were age-
and gender-matched and gave blood samples for reasonsother than AIS between January 2008 and September 2016.
These patients did not suffer from any uncontrolled systemic
diseases such as diabetes mellitus, hypertension, cardiovas-
cular diseases or cancer.
All patients included in the current study were examined
and investigated in terms of parameters such as age, gender,
diabetes mellitus (deﬁned as the fasting blood glucose level
above 126 mg/dl and/or the use of antidiabetic therapy),
hypertension (deﬁned as the systolic blood pressure above
140 mmHg and/or the diastolic blood pressure above
90 mmHg, or the use of antihypertensive therapy), hyperlipid-
emia (deﬁned as the fasting total cholesterol value above
200 mg/dl and/or the triglyceride value above 150 mg/dl),
smoking history (current smoker or having quit in the last 6
months), and body mass index (BMI).
Approval by the ethics committee of Cumhuriyet Universi-
ty was obtained for the study.
2.2. Evaluation of biochemical and hematological
parameters
Blood samples of patients were collected within the ﬁrst 24 h
following AIS. Dry tubes were used for the biochemical
analysis, and EDTA tubes were used for the hematological
test. Whole blood counts of patient and control groups were
analyzed with a Mindray BC-6800 device using Diagon Kits.
Biochemical analyses were performed with a Beckman Coulter
AU5800 device (Beckman Coulter Inc, Hialeah, Florida) using
kits produced by the same company via a fully automatic
nephelometric method.
2.3. Statistical analysis
Data obtained from this study was evaluated by using the SPSS
22.0 program. Continuous data were expressed as the mean
 standard deviation; categorical data were expressed as
percent (%). Data were evaluated with the Kolmogorov–
Smirnov test in terms of normal distribution. The use of an
independent T-test for the analysis of continuous data
showing normal distribution and a Mann–Whitney U-test
for the analysis of variables not showing normal distribution
were planned. However, continuous data obtained from two
different groups did not show normal distribution, therefore,
the Mann–Whitney U-test was used for the analysis. Logistic
regression analysis and the chi-square test were used to
determine the independent risk factors for the 30-day
mortality of patients with AIS. Receiver operating characteris-
tic curve (ROC) analysis was used for determining the
optimum cut-off value of MHR for predicting the 30-day
mortality of patients with AIS. The statistical signiﬁcance level
was accepted as p < 0.05.
3. Results
Comparison of the patient and control groups in terms of
baseline demographic characteristics revealed that there was
no signiﬁcant difference between the two groups in terms of
age, gender, diabetes mellitus status, hypertensive status, BMI
values, statin use, and smoking status. The mean age of the
Fig. 1 – Mean MHR values in control and patient groups.
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 9.6 years.
When the patient and control groups were compared in
terms of laboratory parameters, there was no signiﬁcant
difference between the two groups in terms of creatinine,
hemoglobin, LDL and total cholesterol levels ( p = 0.12, p = 0.59,
p = 0.58, and p = 0.59, respectively). On the other hand, there
were signiﬁcant differences between the two groups in terms
of uric acid, glucose, mean platelet volume (MPV), C-reactive
protein (CRP), platelet, monocyte, lymphocyte, neutrophil and
white blood cell (WBC) counts, HDL and MHR values (Fig. 1).
While uric acid, glucose, MPV, CRP, platelet, monocyte,
neutrophil and WBC counts, and the MHR values were higher
in the patient group, the lymphocyte count and HDL level were
signiﬁcantly higher in the control group (Table 1).
Patients with ischemic stroke were classiﬁed into two
groups according to the 30-day mortality. The ﬁrst group
survived, while patients in the second group died within 30
days after AIS. The comparison of the two groups in terms of
monocyte count, HDL level and MHR value demonstrated that
monocyte count and MHR value of the second group were
statistically higher, while the HDL level was statistically lower
compared to the ﬁrst group ( p < 0.001) (Table 2).
The determination of risk factors related to the 30-day
mortality of AIS patients included age, gender, presence of
diabetes and hypertension, cigarette use, HDL, LDL, total
cholesterol, hemoglobin, CRP, MHR and uric acid, which were
used as independent variables. Application of multivariate
analyses on these parameters showed that uric acid, CRP, and
MHR values were statistically signiﬁcant independent vari-
ables for the prediction of 30-day mortality in AIS patients
(Table 3).
In addition, receiver operating characteristic curve (ROC)
analysis was used for determining the optimum cut-off MHR
value for predicting 30-day mortality in AIS patients. The area
under the curve (AUC) value was calculated as 0.97 (95%
conﬁdence interval (CI) 0.95–0.98). The cut-off MHR value was
observed as 17.52 with a sensitivity of 94.4% and a speciﬁcity of
84.8% (Fig. 2).
4. Discussion
This is the ﬁrst study to demonstrate that patients with AIS
had higher monocyte counts, lower HDL levels, and therefore,higher values of MHR compared to controls. MHR values above
17.52 seem to be an independent risk factor for predicting the
30-day mortality of patients with AIS.
Inﬂammation plays important roles in all pathophysiologi-
cal stages of AIS [4,5]. It is very signiﬁcant in both the
development of AIS and in the post-AIS process. The
components of the immune system lead to the progression
of AIS in various ways. Interactions between lipids and the
various stages of the immune system stimulate premature
atherogenes and adverse atrial electrical and/or structural
remodeling, which may represent a prerequisite for AF [4,11].
Macrophages and monocytes could play a role in the
progress of both atherosclerosis and AF. Endothelial dysfunc-
tion is the ﬁrst step in the subsequent development of
atherosclerosis. After endothelial dysfunction, mononuclear
cells such as monocytes and T lymphocytes attach to the
endothelium. They ﬁrst attach loosely, and then they adhere
tightly to the endothelium and migrate to the subendothelial
space. Afterwards, monocytes mature into macrophages,
which promote inﬂammation and destruction of extracellular
matrix. The macrophages then differentiate into foam cells by
taking oxidized LDL and other lipids via the scavenger
receptors, SR-A and CD-36 [12]. Foam cells that turn into fatty
streaks secrete proinﬂammatory cytokines that stimulate the
local inﬂammatory response around the lesion. These include
matrix metalloproteinases, tissue factors, and growth factors
that initiate smooth muscle replication involved in the
progression of the lesion. Increased activity of metalloprotei-
nases promotes the digestion of the internal elastic lamina,
which subsequently increases the tendency of plaques to
rupture [13]. Tissue factors are frequently located within
macrophage-rich areas within the necrotic center of the
plaque. Thrombosis occurs when tissue factors come in
contact with circulating blood, resulting in occlusion of the
related artery [14]. As can be observed, macrophages and their
precursor cells, the monocytes, play important roles in all
phases of atherosclerosis from fatty streak formation to
plaque rupture, and even in the development of AIS. An
increase in the number of tissue macrophages and circulating
monocytes, which are the source of foam cells, is supposed to
be an indicator of the development of new plaques [15].
Additionally, the production of several cytokines (like
tumor necrosis factor (TNF)-a, interleukin (IL)-1, IL-6, plate-
let-derived endothelial cell growth factor, transforming
growth factor (TGF)-a and-ß, macrophage colony-stimulating
factor, and insulin-like growth factor) are induced after
monocytes adhere to the endothelial cell surface and
extravasate into the damaged tissue [16]. The secretions of
MMP-9 and TGF-ß, which are induced by IL-1b secretion from
macrophages, stimulate ﬁbroblast proliferation [16]. Likewise,
it has been reported that leukocyte activation, especially
monocyte activation, was present in post-operative AF [17].
Therefore, monocytes, which have a long circulation half-life,
and macrophages, which can transform into long-living tissue
macrophages, could play a role in the inﬂammatory response
leading to AF. In accordance with these two conditions, in our
study, we found that the monocyte count was signiﬁcantly
higher in patients with AIS compared to the control group.
After arterial occlusion in brain tissue, the microglia, which
are brain resident macrophages, are activated within minutes.
Table 1 – Comparison of baseline demographic, clinical, and laboratory characteristics of the control and the patient groups.
Control group (n = 408) Patient group (n = 466) X2 value p values
Male, n (%) 184 (45.1%) 208 (44.6%) 0.01 0.92
HT Presence, n (%) 304 (74.5%) 378 (81.1%) 2.76 0.09
DM Presence, n (%) 150 (36.8%) 148 (31.8%) 1.21 0.27
Smoking, n (%) 184 (45.1%) 170 (36.5%) 3.35 0.07
Statin use, n (%) 214 (52.5%) 228 (48.9%) 0.54 0.46
Age (mean  SD)
(min–max)
77.09  6.70
(61–92)
77.35  9.56
(34–98)
0.25
BMI (kg/m2) (mean  SD)
(min–max)
26.39  3.26
(21– 35)
25.86  4.03
(17–35)
0.18
Subgroups according to etiology, n (%) –
Large artery atherosclerosis – 230 (49.4%)
Cardioembolic causes – 166 (35.6%)
Lacunar infarct – 51 (10.9%)
Others – 19 (4.1%)
HDL (mg/dL) (mean  SD)
(min–max)
52.81  28.96
(35–92)
45.93  15.61
(28–75)
<0.001
LDL (mg/dL) (mean  SD)
(min–max)
108.13  7.81
(75–142)
106  7.46
(77–152)
0.58
TotalChol (mg/dL) (mean  SD)
(min–max)
179.45  37.51
(129–267)
175.02  49.13
(38–328)
0.59
Uric acid (mean  SD)
(min–max)
4.04  0.83
(2.1–6.3)
6.41  1.43
(3.8–11.3)
<0.001
Creatine (mg/dL) (mean  SD)
(min–max)
0.80  0.12
(0.56–1.2)
0.78  0.12
(0.56–1.2)
0.12
Hb (g/dL) (mean  SD)
(min–max)
14.32  1.28
(10.2–17.7)
14.18  1.89
(7.8–19)
0.59
Glucose (mg/dL) (mean  SD)
(min–max)
123.42  42.59
(66–248)
127.53  26.95
(67–212)
<0.001
MPV (fL) (mean  SD)
(min–max)
8.89  0.86
(7.1–10.5)
9.45  1.02
(6.8–12.9)
<0.001
CRP (mg/dl) (mean  SD)
(min–max)
5.38  2.46
(1.1–10.1)
10.19  7.52
(2.6–18.4)
<0.001
Platelet (103/L) (mean  SD)
(min–max)
207.52  41.63
(112–313)
276.78  74.90
(20–465)
<0.001
Monocyte (109/ml) (mean  SD)
(min–max)
500.44  94.10
(100–580)
608.03  260.54
(220–1200)
0.002
Lymphocyte (109/ml) (mean  SD)
(min-max)
1787.26  510.08
(600–2900)
1270.69  708.29
(100–4900)
<0.001
Neutrophil (109/ml) (mean  SD) 4647.06  1275.05
(2600–8600)
6420.04  3574.70
(1090–20800)
<0.001
WBC (109/ml) (mean  SD)
(min–max)
6937.26  1935.20
(600–12200)
8370.82  3712.09
(1400–22000)
<0.001
MHR (mean  SD)
(min–max)
9.46  1.13
(2.1–16.6)
13.58  4.67
(5.2–32.84)
<0.001
Italic values are used to demonstrate the statistical signiﬁcance.
Abbreviations: BMI: body mass index; CRP: C-reactive protein; DM: diabetes mellitus; Hb: hemoglobin; HDL: high density lipoprotein; HT:
hypertension; LDL: low density lipoprotein; MHR: monocyte to high density lipoprotein ratio; MPV: mean platelet volume; TotalChol: total
cholesterol; SD: standard deviation; WBC: white blood cell.
Table 2 – Comparison of the mean monocyte count, HDL level and MHR value in patient group after classification into
subgroups according to the mortality within 30-day period.
Surviving group (n = 378) Non-surviving group (n = 88) p values
Monocyte (109/ml) (mean  SD)
(min–max)
534.13  10.99
(220–1030)
925.46  56.25
(305–1200)
<0.001
HDL(mg/dL) (mean  SD)
(min–max)
46.22  1.09
(32–75)
37.07  2.16
(28–67)
<0.001
MHR(mean  SD)
(min–max)
12.34  2.30
(5.20–23.41)
18.91  6.25
(7.64–32.84)
<0.001
Italic values are used to demonstrate the statistical signiﬁcance.
Abbreviations: MHR: monocyte to high density lipoprotein ratio; SD: standard deviation.
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Table 3 – Logistic regression analysis of independent
significant variables in the 30-day mortality in AIS.
ß SE p Exp(B) 95% CI
Uric acid 2.60 0.68 0.001 13.86 3.65–52.65
CRP 0.63 0.18 0.001 1.88 1.32–2.69
MHR 1.84 0.41 0.001 6.32 2.84–14.04
Abbreviations: CI: conﬁdence interval; CRP: C-reactive protein; MHR:
monocyte to high density lipoprotein ratio; SE: standard error; ß:
regression coefﬁcient.
Fig. 2 – Receiver operating characteristic curve of MHR and
30-day mortality in acute ischemic stroke patients.
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prognosis after AIS, are recruited to the ischemic region [18].
This revealed several functional differences between mono-
cyte subtypes in AIS. For example, an experimental rodent
model showed that CCR2+ monocytes (Ly6Chigh) have proin-
ﬂammatory effects, while Ly6Clow monocytes are considered
as anti-inﬂammatory patrolling monocytes [19]. Interestingly,
the recruitment and inﬁltration of pro-inﬂammatory mono-
cytes (Ly6Chigh) into ischemic brain tissue decreased over time
(beginning at day 1 after AIS onset, peaked at day 3 and then
declined at day 7), while the recruitment and inﬁltration of
anti-inﬂammatory monocytes (Ly6Clow) signiﬁcantly in-
creased [19]. Additionally, AIS modulates the peripheral
immune response, triggering brain speciﬁc immune responses
that directly affect the prognosis of AIS patients. A study by
Kaito et al. revealed that the count of the classical monocyte
subtype (CD14++, CD16), which is the equivalent of the rodent
pro-inﬂammatory monocyte subtype (Ly6Chigh), was signiﬁ-
cantly increased in peripheral blood circulation, whereas the
count of the non-classical monocyte subtype, which is the
equivalent of the rodent anti-inﬂammatory monocyte subtype(Ly6Clow), signiﬁcantly decreased in the acute phase of AIS,
which is strongly correlated with the progression and severity
of brain infarction [20]. In addition, clinical studies have shown
that the increased count of classical monocytes, which begin
to increase in the peripheral blood circulation within 3 h after
AIS onset was associated with the severity of brain injury [19].
Therefore, it can be suggested that the prognosis of AIS
patients with high monocyte counts at admission may be
worse than others, a ﬁnding similar to the results of our study.
Anti-inﬂammatory, antioxidant and antithrombotic effects
of HDL have been proven in several studies [21,22]. HDL, which
is classically regarded as an anti-atherogenic lipoprotein,
prevents cholesterol transport to the arterial wall, especially in
the lipid-laden macrophages [23]. In addition, HDL inhibits
endothelial expression of adhesion molecules and effectively
prevents monocyte adhesion to the arterial wall. HDL can also
restrain the inﬂammatory response directly via monocytes
[24]. In an experimental study, Murphy et al., demonstrated
that HDL and its major protein component, apolipoprotein A-1,
showed anti-inﬂammatory effects on human monocytes
through the inhibition of the activation of CD 11b [24].
Therefore, it would not be wrong to suggest that high levels
of HDL cholesterol may have direct protective effects against
atrial myocytes through increased reverse cholesterol trans-
port and indirect effects by increasing the anti-inﬂammatory
and antioxidant effects, which could explain the suppression
of AF development [10]. Consistent with these data, the HDL
level in patients with AIS was found to be statistically lower
than that of the control group in our study. In addition, it has
also been found that the lower levels of HDL are closely related
to mortality in some critical diseases [25]. Similarly, our study
showed that lower HDL levels correlated with mortality in AIS
patients.
The MHR value, deﬁned as the division of monocyte count
to HDL value, is a recently detected inﬂammatory indicator;
however, its association with cardiovascular diseases and
mortality has only been demonstrated in a few studies [26].
Kanbay et al. demonstrated that the increased value of MHR is
an independent risk factor for worsening cardiovascular
events in patients with chronic renal failure [9]. A study by
Karatas suggested that high levels of MHR was independently
correlated with in-hospital major adverse cardiac events
(MACEs) and mortality after primary percutaneous coronary
intervention in patients with ST-segment elevation myocar-
dial infarction [27]. However, to date, there have been no
published studies demonstrating the association between
MHR and prognosis in AIS patients. Based on the literature and
results obtained from our study, we can suggest that a high
MHR value at admission may be an independent predictor of
the 30-day mortality in AIS patients. An MHR value above 17.52
obtained via ROC curve analysis was the cut-off value for
predicting the 30-day mortality in AIS.
The underlying mechanisms between high MHR levels and
the 30-day mortality in AIS are not clearly understood, but as
mentioned above, it is known that monocytes act in the pro-
inﬂammatory direction during the acute phase of AIS, while
HDL acts in the anti-inﬂammatory direction. Moreover, recent
studies have suggested that inﬂammatory processes following
brain injury after AIS may contribute to a poor outcome
[3,4,19,20].
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some limitations. The only end point is the 30-day mortality in
AIS. There was no detailed evaluation according to the
etiologic subtypes of AIS or causes of 30-day mortality. Only
one MHR value was used in the current study; however, the
inﬂammatory process has continuity. The number of patients
is relatively small because our study is a one-centered study.
For these reasons, more detailed and extensive prospective
studies are needed in the future.
In conclusion, we suggest that patients with AIS have
higher monocyte counts, lower HDL levels, and therefore,
higher MHR values compared to the control group. We also
suggest that an MHR value above 17.52 is an independent risk
factor for the 30-day mortality of AIS patients. Further
extensive studies are required regarding this issue.
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